--------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
----------------------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
-----------------------------------------------------
Date of Report (Date of earliest event reported) October 7, 1996
---------------
HYGENICS PHARMACEUTICALS, INC.
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
- --------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
0.22806 33-0120490
- --------- -----------------
(Commission File Number) (IRS Employer Identification No.)
26941 Cabot Road #128 Laguna Hills, California 92653
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (714) 582-7644
<PAGE>
Item 5. Other Events
- ----------------------------
On September 26, 1996, the shareholders resolved by unanimous written consent
to remove Dean Bradley as President, Chief Financial Officer and Director of
the Company. In Mr. Bradley's place, the shareholders elected Charles Newman
as President and Director and Ron Pellet as a Director.
On September 26, 1996, the Directors adopted an unanimous resolution by written
consent approving an Employment Agreement employing Mr. Goedecke as Chief
Executive Officer with a compensation providing for 700,000 shares of restriced
Rule 144 stock and $100,000 per year in deferred salary.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: October 11, 1996 HYGENICS PHARMACEUTICALS, INC.
By: /s/--------------------------------
William Goedecke
Chief Executive Officer
